This platform offers standard in vitro experimentation procedures for the functional validation of candidate genes and biomarkers, and for the efficacy and toxicological evaluation of new drugs, biomaterials and biomarkers.
At the moment, the platform offers standardin vivo experimentation procedures for the evaluation of new therapeutic targets, nanotherapies and biomarkers in the field of oncology and rare diseases.
A new European project awarded to the CIBBIM-Nanomedicine of the VHIR converts the Vall d’Hebron Campus into the health institution with the most active research projects in Nanomedicine of Europe
For the first time, the Vall d’Hebron Campus has a FET Innovation (Future and Emerging Technologies) project that has been awarded within the Horitzo 2020...Read more
The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and...Read more
Nanomedicine & Bioengineering
Book – Nanoparticles in Life Sciences and Biomedicine The creation of new and more efficient therapies for improving human health greatly depends on drug...Read more